{"id":"W4402561069","doi":"10.1016/j.annonc.2024.08.1055","title":"996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Pembrolizumab; Solid tumor; Phase (matter); Oncology; Nuclear medicine; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001015663,0.0008346034,0.001341293,0.0004801747,0.00026989,0.0007495089,0.0005515398,0.0006138167,0.002756173],"category_scores_gemma":[0.0006917686,0.0003736709,0.001236544,0.0005782144,0.0005089621,0.0007604,0.0003094793,0.002157231,0.0007391368],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005949209,"about_ca_system_score_gemma":0.0006576185,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008886072,"about_ca_topic_score_gemma":0.002836878,"domain_scores_codex":[0.9996414,0.000189056,0.00002214547,0.00004662847,0.00003348273,0.00006719471],"domain_scores_gemma":[0.999553,0.0001115797,0.0001000073,0.00004037634,0.00002275894,0.0001722858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6112469,0.02559415,0.01809493,0.001201486,0.00397146,0.0002440721,0.0003121852,0.004765703,0.04385727,0.0002991153,0.005720753,0.284692],"study_design_scores_gemma":[0.4343324,0.4458131,0.08546595,0.0001793288,0.003380699,0.0009578248,0.0002188407,0.003772605,0.01158007,0.0004988402,0.01372095,0.00007939355],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899632,0.005294304,0.0003461917,0.0004541127,0.0001043746,0.0004317952,0.00100233,0.00007630357,0.002327302],"genre_scores_gemma":[0.989392,0.004608391,0.001003613,0.0004806831,0.0001020968,0.000400711,0.002022374,0.00002966848,0.001960307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002756173,"threshold_uncertainty_score":0.009220362,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06164670606560626,"score_gpt":0.3922550541486538,"score_spread":0.3306083480830476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}